BK and JC polyomavirus infections in Tunisian renal transplant recipients. Issue 10 (7th May 2015)

• Record Type: Journal Article
• Authors: Boukoum, Hanen; Nahdi, Imen; Sahtout, Wissal; Skiri, Habib; Aloui, Sabra; Achour, Abdelatif; Segondy, Michel; Aouni, Mahjoub
• Is Part Of: Journal of medical virology. Volume 87:Issue 10(2015:Oct.)
• Page Start: 1788
• Page End: 1795
• Publication Date: 2015-05-07
• Subjects: Virology -- Periodicals; 616
• DOI: 10.1002/jmv.24234
• Languages: English
• ISSNs: 0146-6615

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jmv24234-sec-0001" sec-type="section"> <p>The aim of this prospective study was to investigate the rate of BK (BKPyV) and JC (JCPyV) polyomavirus infections and their influence on allograft function in Tunisian renal transplant recipients. A total of 72 renal transplant recipients were studied. BKPyV and JCPyV were detected and quantified by real‐time PCR in urine and plasma. Demographic and laboratory characteristics were collected for each patient. Polyomavirus DNAuria was detected in 54 (75%) of renal transplant recipients: 26 (36%) had BKPyV DNAuria, 20 (28%) had JCPyV DNAuria, and 8 (11%) had a dual BKPyV/JCPyV DNAuria. BKPyV DNAemia was detected in four (5.5%) patients, whereas no patient had JCPyV viremia. More than 70% of BKPyV and JCPyV infections started within the first 3 months post‐transplant. The risk for positive DNAemia was observed in patients with DNAuria level >10<sup>7</sup>copies/ml. BK Polyomavirus‐associated nephropathy (BKPyVAN) was observed in two patients. This study highlights the high frequency of BKPyV and JCPyV viruria during the first year post‐transplant with the highest incidence observed in the third month. We identified several risk factors that were associated with BKV DNAuria including age, sex of patients, and the use of tacrolimus instead of cyclosporine A at month 3. The use of cyclosporine A instead of tacrolimus was identified as risk factor for JCV viruria in month 3. No statistical difference in the allograft function was found between BKPyV and/or JCPyV infected and uninfected patients. <bold><italic>J. Med. Virol. 87:1788–1795, 2015</italic>.</bold> © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>